SEATTLE GENETICS INC's ticker is SGENXXXX and the CUSIP is 812578102. A total of 300 filers reported holding SEATTLE GENETICS INC in Q4 2017. The put-call ratio across all filers is 0.93 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $229,000 | -89.0% | 2,000 | -91.8% | 0.00% | -94.7% |
| Q3 2019 | $2,090,000 | -10.5% | 24,469 | -27.5% | 0.02% | -17.4% |
| Q2 2019 | $2,335,000 | +36.7% | 33,735 | +11.9% | 0.02% | +15.0% |
| Q4 2018 | $1,708,000 | -46.9% | 30,141 | -27.7% | 0.02% | -47.4% |
| Q3 2018 | $3,214,000 | +322.3% | 41,670 | +263.4% | 0.04% | +280.0% |
| Q2 2018 | $761,000 | -79.5% | 11,466 | -83.8% | 0.01% | -83.1% |
| Q1 2018 | $3,704,000 | +22.6% | 70,766 | +25.3% | 0.06% | +11.3% |
| Q4 2017 | $3,022,000 | +489.1% | 56,495 | +469.7% | 0.05% | +430.0% |
| Q2 2017 | $513,000 | -37.2% | 9,916 | -23.7% | 0.01% | -56.5% |
| Q1 2017 | $817,000 | -2.4% | 13,000 | -18.0% | 0.02% | -32.4% |
| Q4 2016 | $837,000 | +64.8% | 15,858 | +68.7% | 0.03% | 0.0% |
| Q3 2016 | $508,000 | +2.6% | 9,400 | -33.3% | 0.03% | -10.5% |
| Q1 2016 | $495,000 | -57.2% | 14,100 | -45.3% | 0.04% | -70.1% |
| Q4 2015 | $1,157,000 | – | 25,800 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baker Brothers Advisors | 50,060,240 | $5,775,950,000 | 35.57% |
| Lagoda Investment Management, L.P. | 72,969 | $8,419,000 | 9.97% |
| Avidity Partners Management LP | 580,000 | $66,920,000 | 9.25% |
| Arabesque Asset Management Ltd | 14,807 | $1,708,000 | 3.53% |
| Boxer Capital, LLC | 400,000 | $46,152,000 | 3.15% |
| Woodline Partners LP | 364,333 | $42,037,000 | 3.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 56,900 | $6,557,000 | 2.99% |
| SECTORAL ASSET MANAGEMENT INC | 107,000 | $12,346,000 | 2.37% |
| Capital International, Inc./CA/ | 1,197,659 | $138,186,000 | 2.33% |
| Bain Capital Public Equity Management II, LLC | 169,641 | $19,573,000 | 2.29% |